NICE Technology Appraisal Guidance No 66 - the use of newer
drugs for bipolar disorder
NICE Technology
Appraisal Guidance No 66 - the use of newer drugs for bipolar
disorder
NICE Technology Appraisal Guidance No 66 - Olanzapine and
valproate semisodium in the treatment of acute mania associated
with bipolar I disorder
NHSScotland should note that no important differences were
identified for this NICE Guidance, and NHS Quality Improvement
Scotland advises that it is as valid for Scotland as for England
and Wales.
NHSScotland should take account of this NICE Guidance and NHS
Quality Improvement Scotland advice in its planning, funding and
provision of services to ensure that recommended drugs or
treatments are made available to meet clinical need.
NHS Quality Improvement Scotland advice represents the
evidence-based view of NHS Quality Improvement Scotland.
This advice does not override or replace the individual
responsibility of health professionals to make appropriate
decisions in the circumstances of their individual patients, in
consultation with the patient and/or guardian or carer.
No other publication on the NICE Guidance will be issued by NHS
Quality Improvement Scotland.
Hard copies of the NICE Guidance are available from NHS Quality
Improvement Scotland (contact Tracey Smiley, tel 0141 225 6993) and
all NICE Guidance and NHS Quality Improvement Scotland advice is
available on this website.
Published Date: 20 August 2003
